ENGLEWOOD, Colo., Aug. 10,
2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an
innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, rehabilitation, and patient monitoring, announced
that, since its founding, the company has treated more than 1
million patients through its pain management division.
Zynex manufactures and sells the NexWave electrotherapy device,
an FDA-cleared, prescription-strength, non-invasive, and non-opioid
approach to managing acute and chronic pain. The company's pain
management division also distributes and private labels several
high-quality devices such as low-back support, cervical traction,
bracing, and hot/cold therapy. Zynex is bringing a series of
in-patient hospital monitoring devices through FDA clearance in
addition to its pain management and therapeutic products.
Thomas Sandgaard, Founder and
CEO, commented on the company's milestone, "I'm incredibly proud to
have surpassed treating 1 million patients. Reaching such a
tremendous landmark for the company is a testament to the tireless
efforts and teamwork that each of our employees brings to this
company.
"Our journey to this moment has been filled with challenges,
growth, and triumphs, and it's awe-inspiring to think about the
countless lives we've touched. Success is not measured merely in
numbers, but also in the positive change we've effected through
proven non-opioid pain relief."
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and
sells medical devices used for pain management and rehabilitation
as well as non-invasive fluid, sepsis, and laser-based pulse
oximetry monitoring systems for use in hospitals. For additional
information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zynex-announces-1-millionth-patient-milestone-301897681.html
SOURCE Zynex